Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'reduced haloperidol' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 116 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Beumer, JH; Bosman, IJ; Maes, R
      Hair as a biological specimen for therapeutic drug monitoring

      INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
    2. Desai, HD; Seabolt, J; Jann, MW
      Smoking in patients receiving psychotropic medications - A pharmacokineticperspective

      CNS DRUGS
    3. Yasui-Furukori, N; Kondo, T; Suzuki, A; Mihara, K; Tokinaga, N; Inoue, Y; Otani, K; Kaneko, S
      Effect of the CYP2D6 genotype on prolactin concentration in schizophrenic patients treated with haloperidol

      SCHIZOPHRENIA RESEARCH
    4. Roh, HK; Chung, JY; Oh, DY; Park, CS; Svensson, JO; Dahl, ML; Bertilsson, L
      Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    5. Shin, JG; Kane, K; Flockhart, DA
      Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    6. Jann, MW; Chang, WH; Lane, HY
      Differences in haloperidol epidemiologic pharmacokinetic studies

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    7. Lam, LCW; Garcia-Barcelo, MM; Ungvari, GS; Tang, WK; Lam, VKL; Kwong, SL; Lau, BST; Kwong, PPK; Waye, MMY; Chiu, HFK
      Cytochrome P450 2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients

      PHARMACOPSYCHIATRY
    8. Suzuki, Y; Someya, T; Shimoda, K; Hirokane, G; Morita, S; Yokono, A; Inoue, Y; Takahashi, S
      Importance of the cytochrome P450 2D6 genotype for the drug metabolic interaction between chlorpromazine and haloperidol

      THERAPEUTIC DRUG MONITORING
    9. Fang, J; Mckay, G; Song, JX; Remillrd, A; Li, XM; Midha, K
      In vitro characterization of the metabolism of haloperidol using recombinant cytochrome P450 enzymes and human liver microsomes

      DRUG METABOLISM AND DISPOSITION
    10. Takiguchi, Y; Ishihara, R; Kato, R; Kamihara, S; Yokota, M; Uematsu, Y
      Measurement of flecainide in hair as an index of drug exposure

      JOURNAL OF PHARMACEUTICAL SCIENCES
    11. Schur, BC; Bjerke, J; Nuwayhid, N; Wong, SH
      Genotyping of cytochrome P450 2D6*3 and*4 mutations using conventional PCR

      CLINICA CHIMICA ACTA
    12. Seno, H; Hattori, H; Ishii, A; Kumazawa, T; Watanabe-Suzuki, K; Suzuki, O
      Analyses of butyrophenones and their analogues in whole blood by high-performance liquid chromatography-electrospray tandem mass spectrometry

      JOURNAL OF CHROMATOGRAPHY B
    13. Takeshita, M; Miura, M; Ohkubo, T; Sugawara, K
      Asymmetric redox reactions in human liver stereoselective oxidation of optically active dihydrohaloperidols, dihydrobromoperidols and stereospecific reduction of haloperidol and bromoperidol

      ENANTIOMER
    14. Porter, SJ; Somogyi, AA; White, JM
      Kinetics and inhibition of the formation of 6 beta-naltrexol from naltrexone in human liver cytosol

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    15. Fukuda, R
      Factors affecting serum haloperidol level assessed by longitudinal therapeutic monitoring

      PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
    16. Someya, T; Muratake, T; Hirokane, G; Shibasaki, M; Shimoda, K; Takahashi, S
      Interindividual variation in bromperidol metabolism and relationship to therapeutic effects

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    17. Shimoda, K; Morita, S; Yokono, A; Someya, T; Hirokane, G; Sunahara, N; Takahashi, S
      CYP2D6*10 alleles are not the determinant of the plasma haloperidol concentrations in Asian patients

      THERAPEUTIC DRUG MONITORING
    18. Mihara, K; Suzuki, A; Kondo, T; Yasui, N; Furukori, H; Nagashima, U; Ono, S; Kaneko, S; Otani, K; Inoue, Y
      Effect of a genetic polymorphism of CYP1A2 inducibility on the steady state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia

      THERAPEUTIC DRUG MONITORING
    19. Inoue, A; Sugita, S; Shoji, H; Ichimoto, H; Hide, I; Nakata, Y
      Repeated haloperidol treatment decreases sigma(1) receptor binding but does not affect its mRNA levels in the guinea pig or rat brain

      EUROPEAN JOURNAL OF PHARMACOLOGY
    20. Breyer-Pfaff, U; Nill, K
      High-affinity stereoselective reduction of the enantiomers of ketotifen and of ketonic nortriptyline metabolites by aldo-keto reductases from human liver

      BIOCHEMICAL PHARMACOLOGY
    21. Silvestri, S; Seaman, MV; Negrete, JC; Houle, S; Shammi, CM; Remington, GJ; Kapur, S; Zipursky, RB; Wilson, AA; Christensen, BK; Seeman, P
      Increased dopamine D-2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study

      PSYCHOPHARMACOLOGY
    22. Someya, T; Suzuki, Y; Shimoda, K; Hirokane, G; Morita, S; Yokono, A; Inoue, Y; Takahashi, S
      The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: A preliminary study in a psychiatric population

      PSYCHIATRY AND CLINICAL NEUROSCIENCES
    23. Watanabe, M; Tateishi, T; Asoh, M; Nakura, H; Tanaka, M; Kumai, T; Kobayashi, S
      Role of CYP3A in haloperidol N-dealkylation and pharmacokinetics in rats

      FUNDAMENTAL & CLINICAL PHARMACOLOGY
    24. Hempenius, J; Steenvoorden, RJJM; Lagerwerf, FM; Wieling, J; Jonkman, JHG
      'High throughput' solid-phase extraction technology and turbo ionspray LC-MS-MS applied to the determination of haloperidol in human plasma

      JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
    25. Aitchison, KJ; Munro, J; Wright, P; Smith, S; Makoff, AJ; Sachse, C; Sham, PC; Murray, RM; Collier, DA; Kerwin, RW
      Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    26. Aymard, N; Viala, A; Baldacci, C; Smagghe, PO; Vacheron, MN; Caroli, F
      Pharmacoclinical strategy in neuroleptic resistant schizophrenic patients treated by clozapine: Clinical evolution, concentration of plasma and red blood cell clozapine and desmethylclozapine, whole blood serotonin and tryptophan

      PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
    27. Ulrich, S; Neuhof, S; Braun, V; Meyer, FP
      Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    28. Yasui, N; Kondo, T; Suzuki, A; Otani, K; Mihara, K; Furukori, H; Kaneko, S; Inoue, Y
      Lack of significant pharmacokinetic interaction between haloperidol and grapefruit juice

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    29. Shimoda, K; Someya, T; Morita, S; Hirokane, G; Noguchi, G; Yokono, A; Shibasaki, M; Takahashi, S
      Lower plasma levels of haloperidol in smoking than in nonsmoking schizophrenic patients

      THERAPEUTIC DRUG MONITORING
    30. Watanabe, M; Tateishi, T; Tanaka, M; Kumai, T; Kobayashi, S
      Role of CYP3A in bromperidol metabolism in rat in vitro and in vivo

      XENOBIOTICA
    31. Wu, SM; Ko, WK; Wu, HL; Chen, SH
      Trace analysis of haloperidol and its chiral metabolite in plasma by capillary electrophoresis

      JOURNAL OF CHROMATOGRAPHY A
    32. Walter, S; Bauer, S; Roots, I; Brockmoller, J
      Quantification of the antipsychotics flupentixol and haloperidol in human serum by high-performance liquid chromatography with ultraviolet detection

      JOURNAL OF CHROMATOGRAPHY B
    33. BOEHME CL; STROBEL HW
      HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC METHODS FOR THE ANALYSIS OF HALOPERIDOL AND CHLORPROMAZINE METABOLISM IN-VITRO BY PURIFIED CYTOCHROME-P450 ISOFORMS

      Journal of chromatography B. Biomedical sciences and applications
    34. SHIMODA K; SOMEYA T; MORITA S; HIROKANE G; YOKONO A; SHIBASAKI M; TAKAHASHI S
      PLASMA-CONCENTRATIONS OF TIMIPERONE AND ITS REDUCED METABOLITE IN THEPATIENTS ON TIMIPERONE

      Psychiatry and clinical neurosciences ( Psychiatry and clinical neurosciences (Carlton. Print))
    35. Lee, MS; Han, CS; Woonyou, Y; Kim, SH
      Co-administration of sertraline and haloperidol

      PSYCHIATRY AND CLINICAL NEUROSCIENCES
    36. BELLIOTTI TR; BRINK WA; KESTEN SR; RUBIN JR; WUSTROW DJ; ZOSKI KT; WHETZEL SZ; CORBIN AE; PUGSLEY TA; HEFFNER TG; WISE LD
      ISOINDOLINONE ENANTIOMERS HAVING AFFINITY FOR THE DOPAMINE D-4 RECEPTOR

      Bioorganic & medicinal chemistry letters
    37. PAN LP; DEVRIENDT C; BELPAIRE FM
      IN-VITRO CHARACTERIZATION OF THE CYTOCHROME-P450 ISOENZYMES INVOLVED IN THE BACK OXIDATION AND N-DEALKYLATION OF REDUCED HALOPERIDOL

      Pharmacogenetics
    38. EYLES DW; MCGRATH JJ; STEDMAN TJ; POND SM
      CHIRALITY OF REDUCED HALOPERIDOL IN HUMANS

      European neuropsychopharmacology
    39. SHIMODA K; SHIBASAKI M; INABA T; CHEUNG SW; SOMEYA T; TAKAHASHI S
      CARBONYL REDUCTION OF TIMIPERONE IN HUMAN LIVER CYTOSOL

      Pharmacology & toxicology
    40. Otsuka, K; Honda, S; Kato, J; Terabe, S; Kimata, K; Tanaka, N
      Effects of compositions of dimethyl-beta-cyclodextrins on enantiomer separations by cyclodextrin modified capillary zone electrophoresis

      JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
    41. GRIMM JW; ARAVAGIRI M; SEE RE
      OVARIECTOMY RESULTS IN LOWER PLASMA HALOPERIDOL LEVELS IN RATS FOLLOWING CHRONIC ADMINISTRATION

      Pharmaceutical research
    42. Usuki, E; Van der Schyf, CJ; Castagnoli, N
      Metabolism of haloperidol and its tetrahydropyridine dehydration product HPTP

      DRUG METABOLISM REVIEWS
    43. ULRICH S; WURTHMANN C; BROSZ M; MEYER FP
      THE RELATIONSHIP BETWEEN SERUM CONCENTRATION AND THERAPEUTIC EFFECT OF HALOPERIDOL IN PATIENTS

      Clinical pharmacokinetics
    44. CHANG WH; LIN SK; LANE HY; WEI FC; HU WH; LAM YWF; JANN MW
      REVERSIBLE METABOLISM OF CLOZAPINE AND CLOZAPINE N-OXIDE IN SCHIZOPHRENIC-PATIENTS

      Progress in neuro-psychopharmacology & biological psychiatry
    45. ULRICH S; NEUHOF S; BRAUN V; MEYER FP
      THERAPEUTIC WINDOW OF SERUM HALOPERIDOL CONCENTRATION IN ACUTE SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER

      Pharmacopsychiatry
    46. PAN LP; ROSSEEL MT; BELPAIRE FM
      COMPARISON OF 2 HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC METHODS FOR MONITORING PLASMA-CONCENTRATIONS OF HALOPERIDOL AND REDUCED HALOPERIDOL

      Therapeutic drug monitoring
    47. TENEICK AP; NAKAMURA H; REED MD
      DRUG-DRUG INTERACTIONS IN PEDIATRIC PSYCHOPHARMACOLOGY

      The Pediatric clinics of North America
    48. WRIGHT AM; BEMPONG J; KIRBY ML; BARLOW RL; BLOOMQUIST JR
      EFFECTS OF HALOPERIDOL METABOLITES ON NEUROTRANSMITTER UPTAKE AND RELEASE - POSSIBLE ROLE IN NEUROTOXICITY AND TARDIVE-DYSKINESIA

      Brain research
    49. HOJA H; MARQUET P; VERNEUIL B; LOTFI H; DUPUY JL; PENICAUT B; LACHATRE G
      DETERMINATION OF HALOPERIDOL AND ITS REDUCED METABOLITE IN HUMAN PLASMA BY LIQUID-CHROMATOGRAPHY MASS-SPECTROMETRY WITH ELECTROSPRAY-IONIZATION

      Journal of chromatography B. Biomedical sciences and applications
    50. SUZUKI A; OTANI K; MIHARA K; YASUI N; KANEKO S; INOUE Y; HAYASHI K
      EFFECTS OF THE CYP2D6 GENOTYPE ON THE STEADY-STATE PLASMA-CONCENTRATIONS OF HALOPERIDOL AND REDUCED HALOPERIDOL IN JAPANESE SCHIZOPHRENIC-PATIENTS

      Pharmacogenetics
    51. TAKESHITA M; MIURA M; HONGO T; OHKUBO T; SUGAWARA K; KOSAKA K; TAKESHITA Y; ARAKI T; OSHIMA Y
      SYNTHESIS AND CATALEPTIC EFFECTS OF OPTICALLY-ACTIVE DIHYDROHALOPERIDOLS AND DIHYDROBROMOPERIDOLS

      Chirality
    52. PAN LP; WIJNANT P; DEVRIENDT C; ROSSEEL MT; BELPAIRE FM
      CHARACTERIZATION OF THE CYTOCHROME-P450 ISOENZYMES INVOLVED IN THE IN-VITRO N-DEALKYLATION OF HALOPERIDOL

      British journal of clinical pharmacology
    53. JANN MW; CRABTREE BL; PITTS WM; LAM YWF; CARTER JG
      PLASMA ALPHA-ONE ACID GLYCOPROTEIN AND HALOPERIDOL CONCENTRATIONS IN SCHIZOPHRENIC-PATIENTS

      Neuropsychobiology
    54. LANE HY; LIN HN; HU OYP; CHEN CC; JANN MW; CHANG WH
      BLOOD-LEVELS OF REDUCED HALOPERIDOL VERSUS CLINICAL EFFICACY AND EXTRAPYRAMIDAL SIDE-EFFECTS OF HALOPERIDOL

      Progress in neuro-psychopharmacology & biological psychiatry
    55. FANG J; BAKER GB; SILVERSTONE PH; COUTTS RT
      INVOLVEMENT OF CYP3A4 AND CYP2D6 IN THE METABOLISM OF HALOPERIDOL

      Cellular and molecular neurobiology
    56. GUTHRIE SK; HARIHARAN M; KUMAR AA; TANDON R
      THE EFFECT OF PAROXETINE ON THIOTHIXENE PHARMACOKINETICS

      Journal of clinical pharmacy and therapeutics
    57. LANE HY; HU OYP; JANN MW; DENG HC; LIN HN; CHANG WH
      DEXTROMETHORPHAN PHENOTYPING AND HALOPERIDOL DISPOSITION IN SCHIZOPHRENIC-PATIENTS

      Psychiatry research
    58. AYMARD N; BALDACCI C; LEYRIS A; SMAGGHE PO; TRIBOLET S; VACHERON MN; VIALA A; CAROLI F
      NEUROLEPTIC-RESISTANT SCHIZOPHRENIC-PATIENTS TREATED BY CLOZAPINE - CLINICAL EVOLUTION, PLASMA AND RED-BLOOD-CELL CLOZAPINE AND DESMETHYLCLOZAPINE LEVELS

      Therapie
    59. WU HL; WU SM; CHEN SH; OTSUKA K; TERABE S
      ENANTIOSEPARATION OF REDUCED HALOPERIDOL BY CAPILLARY ZONE ELECTROPHORESIS WITH DIMETHYL-BETA-CYCLODEXTRIN

      Journal of the Chinese Chemical Society
    60. FUJII T; HATANAKA K; SATO G; YASUI Y; ARIMOTO H; MITSUTSUKA Y
      SELECTIVE DETERMINATION OF HALOPERIDOL IN HUMAN SERUM - SURFACE-IONIZATION MASS-SPECTROMETRY AND GAS-CHROMATOGRAPHY WITH SURFACE-IONIZATIONDETECTION

      Journal of chromatography B. Biomedical applications
    61. VERWEIJ AMA; HORDIJK ML; LIPMAN PJL
      LIQUID-CHROMATOGRAPHIC THERMOSPRAY TANDEM MASS-SPECTROMETRIC QUANTITATIVE-ANALYSIS OF SOME DRUGS WITH HYPNOTIC, SEDATIVE AND TRANQUILIZING PROPERTIES IN WHOLE-BLOOD

      Journal of chromatography B. Biomedical applications
    62. ELSAYED YM; KHIDR SH; NIAZY EM
      HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ASSAY FOR THE DETERMINATION OF HALOPERIDOL IN PLASMA

      Journal of liquid chromatography & related technologies
    63. LACRO JP; KUCZENSKI R; ROZNOSKI M; WARREN KA; HARRIS MJ; JESTE DV
      OLDER PSYCHOTIC-PATIENTS

      The American journal of geriatric psychiatry
    64. LAVIN MR; SIRIS SG; MASON SE
      WHAT IS THE CLINICAL IMPORTANCE OF CIGARETTE-SMOKING IN SCHIZOPHRENIA

      The American journal on addictions
    65. CHANG WH; JANN MW; CHIANG TS; LIN HN; HU WH; CHIEN CP
      PLASMA HALOPERIDOL AND REDUCED HALOPERIDOL CONCENTRATIONS IN A GERIATRIC POPULATION

      Neuropsychobiology
    66. JANN MW; WEI FC; LIN HN; CHING PC; CHANG WH
      HALOPERIDOL AND REDUCED HALOPERIDOL PLASMA-CONCENTRATIONS AFTER A LOADING DOSE REGIMEN WITH HALOPERIDOL DECANOATE

      Progress in neuro-psychopharmacology & biological psychiatry
    67. KIM YH; CHA IJ; SHIM JC; SHIN JG; YOON YR; KIM YK; KIM JI; PARK GH; JANG IJ; WOO JI; SHIN SG
      EFFECT OF RIFAMPIN ON THE PLASMA-CONCENTRATION AND THE CLINICAL EFFECT OF HALOPERIDOL CONCOMITANTLY ADMINISTERED TO SCHIZOPHRENIC-PATIENTS

      Journal of clinical psychopharmacology
    68. BARBHAIYA RH; SHUKLA UA; GREENE DS; BREUEL HP; MIDHA KK
      INVESTIGATION OF PHARMACOKINETIC AND PHARMACODYNAMIC INTERACTIONS AFTER COADMINISTRATION OF NEFAZODONE AND HALOPERIDOL

      Journal of clinical psychopharmacology
    69. DEOLIVEIRA IR; DESENA EP; PEREIRA ELA; MIRANDA AMA; DEOLIVEIRA NF; RIBEIRO MG; DECASTROESILVA E; DARDENNES RM; SAMUELLAJEUNESSE B; MARCILIO C
      HALOPERIDOL BLOOD-LEVELS AND CLINICAL OUTCOME - A METAANALYSIS OF STUDIES RELEVANT TO TESTING THE THERAPEUTIC WINDOW HYPOTHESIS

      Journal of clinical pharmacy and therapeutics
    70. GOULLE JP; KINTZ P
      HAIR TESTING - A NEW TOOL FOR CLINICAL IN VESTIGATION

      La Revue de medecine interne
    71. WEI FC; JANN MW; LIN HN; CHING PC; CHANG WH
      A PRACTICAL LOADING DOSE METHOD FOR CONVERTING SCHIZOPHRENIC-PATIENTSFROM ORAL TO DEPOT HALOPERIDOL THERAPY

      The Journal of clinical psychiatry
    72. MEYER MC; BALDESSARINI RJ; GOFF DC; CENTORRINO F
      CLINICALLY SIGNIFICANT INTERACTIONS OF PSYCHOTROPIC AGENTS WITH ANTIPSYCHOTIC-DRUGS

      Drug safety
    73. HUANG HF; JANN MW; WEI FC; CHANG TP; CHEN JS; JUANG DJ; LIN SK; LAM YWF; CHIEN CP; CHANG WH
      LACK OF PHARMACOKINETIC INTERACTION BETWEEN BUSPIRONE AND HALOPERIDOLIN PATIENTS WITH SCHIZOPHRENIA

      Journal of clinical pharmacology
    74. BALANT LP; GEXFABRY M; BALANTGORGIA E
      DRUG-METABOLISM AS A CONFOUNDING FACTOR IN PK PD POPULATION APPROACHES/

      Therapie
    75. AVENT KM; USUKI E; EYLES DW; KEEVE R; VANDERSCHYF CJ; CASTAGNOLI N; POND SM
      HALOPERIDOL AND ITS TETRAHYDROPYRIDINE DERIVATIVE (HPTP) ARE METABOLIZED TO POTENTIALLY NEUROTOXIC PYRIDINIUM SPECIES IN THE BABOON

      Life sciences
    76. MIZUNO A; UEMATSU T; GOTOH S; KATOH E; NAKASHIMA M
      THE MEASUREMENT OF CAFFEINE CONCENTRATION IN SCALP HAIR AS AN INDICATOR OF LIVER-FUNCTION

      Journal of Pharmacy and Pharmacology
    77. LYNCH DR; GALLAGHER MJ
      INHIBITION OF N-METHYL-D-ASPARTATE RECEPTORS BY HALOPERIDOL - DEVELOPMENTAL AND PHARMACOLOGICAL CHARACTERIZATION IN NATIVE AND RECOMBINANT RECEPTORS

      The Journal of pharmacology and experimental therapeutics
    78. MONNET FP; DECOSTA BR; BOWEN WD
      DIFFERENTIATION OF SIGMA-LIGAND-ACTIVATED RECEPTOR SUBTYPES THAT MODULATE NMDA-EVOKED [H-3] NORADRENALINE RELEASE IN RAT HIPPOCAMPAL SLICES

      British Journal of Pharmacology
    79. EYLES DW; MCGRATH JJ; POND SM
      FORMATION OF PYRIDINIUM SPECIES OF HALOPERIDOL IN HUMAN LIVER AND BRAIN

      Psychopharmacology
    80. OZKAN S; BIRYOL I
      DETERMINATION OF HALOPERIDOL IN PHARMACEUTICAL DOSAGE FORMS BY REDUCTION IN A SPECIALLY ACTIVATED GLASSY-CARBON ELECTRODE

      STP pharma sciences
    81. VANDEL S; BERTSCHY G; BAUMANN P; BOUQUET S; BONIN B; FRANCOIS T; SECHTER D; BIZOUARD P
      FLUVOXAMINE AND FLUOXETINE - INTERACTION STUDIES WITH AMITRIPTYLINE, CLOMIPRAMINE AND NEUROLEPTICS IN PHENOTYPED PATIENTS

      Pharmacological research
    82. BEHL C; RUPPRECHT R; SKUTELLA T; HOLSBOER F
      HALOPERIDOL-INDUCED CELL DEATH-MECHANISM AND PROTECTION WITH VITAMIN-E IN-VITRO

      NeuroReport
    83. LANE HY; LIN HN; HWU HG; JANN M; HU WH; CHANG WH
      HALOPERIDOL PLASMA-CONCENTRATIONS IN TAIWANESE PSYCHIATRIC-PATIENTS

      Journal of the Formosan Medical Association
    84. ARAVAGIRI M; MARDER SR; YUWILER A; MIDHA KK; KULA NS; BALDESSARINI RJ
      DISTRIBUTION OF FLUPHENAZINE AND ITS METABOLITES IN BRAIN-REGIONS ANDOTHER TISSUES OF THE RAT

      Neuropsychopharmacology
    85. CHANG WH; JUANG DJ; LIN SK; HUANG JD; LAM YWF; JANN MW; CHIEN CP
      DISPOSITION OF HALOPERIDOL AND REDUCED HALOPERIDOL PLASMA-LEVELS AFTER SINGLE-DOSE HALOPERIDOL DECANOATE ADMINISTRATION

      Human psychopharmacology
    86. DEOLIVEIRA IR; DARDENNES RM; AMORIM ES; DIQUET B; DESENA EP; MOREIRA EC; DECASTROESILVA EJ; PAYAN C; FERMANIAN J; MARCILIO C; SAMUELLAJEUNESSE B
      IS THERE A RELATIONSHIP BETWEEN ANTIPSYCHOTIC BLOOD-LEVELS AND THEIR CLINICAL EFFICACY - AN ANALYSIS OF STUDIES DESIGN AND METHODOLOGY

      Fundamental and clinical pharmacology
    87. MILTON GV; JANN MW
      EMERGENCY TREATMENT OF PSYCHOTIC SYMPTOMS - PHARMACOKINETIC CONSIDERATIONS FOR ANTIPSYCHOTIC-DRUGS

      Clinical pharmacokinetics
    88. UEMATSU T; KOSUGE K; ARAKI S; ISHIYE M; ASAI Y; NAKASHIMA M
      TIME-COURSE OF APPEARANCE OF OFLOXACIN IN HUMAN SCALP HAIR AFTER ORAL-ADMINISTRATION

      Therapeutic drug monitoring
    89. GUPTA SK; KUNKA RL; METZ A; LLOYD T; RUDOLPH G; PEREL JM
      EFFECT OF ALOSETRON (A NEW 5-HT3 RECEPTOR ANTAGONIST) ON THE PHARMACOKINETICS OF HALOPERIDOL IN SCHIZOPHRENIC-PATIENTS

      Journal of clinical pharmacology
    90. BRENT PJ
      HALOPERIDOL AND REDUCED HALOPERIDOL-INDUCED EXACERBATION OF THE DYSTONIA PRODUCED BY THE KAPPA-OPIOID U50,488H IN GUINEA-PIGS IS ASSOCIATEDWITH INHIBITION OF SIGMA-BINDING SITES - BEHAVIORAL AND AUTORADIOGRAPHICAL STUDIES

      Brain research
    91. FANG J; YU PH
      EFFECT OF HALOPERIDOL AND ITS METABOLITES ON DOPAMINE AND NORADRENALINE UPTAKE IN RAT BRAIN-SLICES

      Psychopharmacology
    92. MIDHA KK; HUBBARD JW; MARDER SR; MARSHALL BD; VANPUTTEN T
      IMPACT OF CLINICAL PHARMACOKINETICS ON NEUROLEPTIC THERAPY IN PATIENTS WITH SCHIZOPHRENIA

      Journal of psychiatry & neuroscience
    93. DYSKEN MW; JOHNSON SB; HOLDEN L; VATASSERY G; NYGREN J; JELINSKI M; KUSKOWSKI M; SCHUT L; MCCARTEN JR; KNOPMAN D; MALETTA GJ; SKARE S
      HALOPERIDOL CONCENTRATIONS IN PATIENTS WITH ALZHEIMERS DEMENTIA

      The American journal of geriatric psychiatry
    94. UEMATSU T; OHSAWA Y; MIZUNO A; NAKASHIMA M
      ANALYSIS OF A NEW FLUOROQUINOLONE DERIVATIVE (Q-35) IN HUMAN SCALP HAIR AS AN INDEX OF DRUG EXPOSURE AND AS A TIME MARKER IN HAIR

      International journal of legal medicine
    95. CHANG WH; SHIEH YS; LIU HC; JANN MW; CHIEN CP
      PLASMA REDUCED HALOPERIDOL HALOPERIDOL RATIOS IN SCHIZOPHRENIC-PATIENTS TREATED WITH HIGH DOSAGES OF HALOPERIDOL/

      European neuropsychopharmacology
    96. LEROUX JM; ELIA E; JACQUET M; POMMERY J; LEVRON JC; BOUHOURS P; ERB F; SECHTER D
      CORRELATION OF CLINICAL-RESPONSE (PANSS) AND PLASMA-LEVELS OF HALOPERIDOL AND REDUCED HALOPERIDOL IN SCHIZOPHRENIA

      Progress in neuro-psychopharmacology & biological psychiatry
    97. TSANG MW; SHADER RI; GREENBLATT DJ
      METABOLISM OF HALOPERIDOL - CLINICAL IMPLICATIONS AND UNANSWERED QUESTIONS

      Journal of clinical psychopharmacology
    98. DODDI S; RIFKIN A; KARAJGI B; COOPER T; BORENSTEIN M
      BLOOD-LEVELS OF HALOPERIDOL AND CLINICAL OUTCOME IN SCHIZOPHRENIA

      Journal of clinical psychopharmacology
    99. HOFFMAN DW; EDKINS RD
      SOLID-PHASE EXTRACTION AND HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY FORTHERAPEUTIC MONITORING OF HALOPERIDOL LEVELS

      Therapeutic drug monitoring
    100. JAVAID JI
      CLINICAL PHARMACOKINETICS OF ANTIPSYCHOTICS

      Journal of clinical pharmacology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 12/12/19 alle ore 15:29:35